ABBV — AbbVie
Health Care|Biotechnology
3 Articles
ABBVEarningspositive
AbbVie Beats Q1 Earnings Despite IPR&D Headwinds, Raises Full-Year Guidance
AbbVie reported Q1 2026 adjusted EPS of $2.65, up 7.7% YoY, beating expectations despite $0.41 IPR&D impact. Revenue jumped 12.4% to $15B as Skyrizi and Rinvoq offset Humira declines.
4 min read
ABBVEarningsneutral
AbbVie Takes $744M R&D Charge, Trims Q1 Earnings Guidance by $0.41 Per Share
AbbVie disclosed a $744 million charge for acquired R&D and milestone payments in Q1 2026, reducing quarterly EPS guidance to $2.56-$2.60 while maintaining full-year outlook.
2 min read
ABBVInsider Tradingneutral
9 AbbVie Executives Awarded Stock Grants in Coordinated February Move
All of AbbVie's senior leadership received simultaneous stock awards on February 18, 2026, signaling unified executive compensation timing.
3 min read